Complication: renal complications (moderate or severe) (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in complication: renal complications (moderate or severe) (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Complication: respiratory failure (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in complication: respiratory failure (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Complication: bowel ischaemia (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair may leads to lower complication: bowel ischaemia (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Mortality (6 months) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in mortality (6 months) compared with conventional open repair (moderate certainty).
1 finding from 1 review
Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
1 finding from 1 review
Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review